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Abstract 
Viral infections cause a major stress in host cells. The cellular responses to stress are 
mediated by p53, which by deregulation of cell cycle and apoptosis, may also be part of the host cell 
reaction to fight infections. Therefore, during evolutionary viral adaptation to host organisms, viruses 
have developed strategies to manipulate host cell p53 dependent pathways to facilitate their viral life 
cycles. Thus, interference with p53 function is an important component in viral pathogenesis. Many 
viruses have proteins that directly affect p53, while others alter the regulation of p53 in an indirect 
manner, mediated by hdm2 or akt, or induction of interferon. Rescue of p53 activity is becoming an 
area of therapeutic development in oncology. It might be feasible that manipulation of p53 mediated 
responses can become a therapeutic option to limit viral replication or dissemination. In this report, 
the mechanisms by which viral proteins manipulate p53 responses are reviewed, and it is proposed 
that a pharmacological rescue of p53 functions might help to control viral infections. 
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Introduction 
Cellular stress responses aim to protect cells from many different types of stress damage, 
endogenous and exogenous, and among of these viral infections represent a major type of cellular 
stress. Viruses require a suitable host cell to carry out their life cycle. In infections, viruses aim to use 
the host cell to guarantee their own survival and propagation. Therefore, the human pathology 
observed in virally infected individuals is a consequence and side effect, but not the aim of the virus 
in the course of an infection. Actually a very pathogenic infection might be self limiting, because it 
runs the risk of eliminating suitable host individuals for viral transmission and perpetuation. However, 
if cellular stress responses were very successful, viral infections probably would not be viable, since 
they would be aborted by host cells before completion of the viral life cycle. These cellular stress 
responses are largely mediated by p53 [1, 2]. Therefore, during viral evolution and their adaptation to 
human host cells, viruses have acquired different strategies to manipulate cellular stress responses, 
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mediated in large part by p53, which will permit viral survival by allowing completion of all the steps 
in the viral life cycle, without compromising host viability. The rapid viral life cycle also means that 
viral effects on p53 are transitory, and perhaps function differently at specific times within the host 
cell cycle. For many human viruses, for example HBV or HPV, their viral pathogenic effects are very 
difficult to study in synchronized cell cultures, and therefore these effects cannot be easily detected 
due to their short duration and the heterogeneity of infected cells. In this work is presented an 
overview of how p53 functions can be interfered with by viral proteins from many different viruses, 
and is thus a common aspect to all infections that can become a potentially useful therapeutic target. 
 
The p53-Hdm2 regulatory circuit as mediator of cellular stress responses, a prime target for 
viral proteins 
 The p53 protein functions as a common  integrator and transmitter of signals originated in 
signaling pathways which are activated in the cellular response to many different types of stress, such 
a DNA damage, changes in osmolarity, temperatute and  changes in oxygen levels among others [3, 
4]. The response induced by p53 [5] regulates biological functions, ranging from cell cycle regulation 
[6], induction of apoptosis [7], autophagy [8] or senescence [9], all aiming to protect the cell and the 
individual organism. The p53 protein also controls mechanisms implicated in DNA replication by its 
contribution to cell cycle checkpoints [10], and can also initiate responses that lead to cell death [11]. 
Mechanistically, the p53 protein functions as a transcriptional regulator of genes implicated in these 
different cellular functions [12, 13], and because of its regulatory roles p53 behaves as a tumor 
suppressor gene [14, 15].  
  The p53 protein has a short half-life and its intracellular basal levels are low in normal cells. 
In response to stress p53 is immediately activated by phosphorylation mediated by different kinases, 
which represent different response pathways to cellular stress of which the response to DNA damage, 
have received most of the research attention for its oncogenic consequences [15-17]. This rapid 
phosphorylation of p53 results in its stabilization and accumulation, which is mediated by a large 
number of different cellular kinases, such as ATM, ATR, CHK1, CHK2, JNK, VRK1, PLK3, CK1 
among others [18]. Seven different residues in the p53 N-terminal trans-activation domain 1 (TAD1) 
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are targeted by kinases [18], and the resulting patterns of p53 phosphorylation determine its protein 
interactions with transcriptional activators, or negative regulatory proteins, such as hdm2/mdm2 and 
other ubiquitin ligases [18-20], some might be viral proteins, and in this way phosphorylation 
determines the specificity of the response, which may be different depending on cell type. This 
phosphorylated N-terminal domain promotes binding to transcriptional coactivators, such as p300 or 
PCAF, which acetylates p53 in its carboxy terminus [21]. The activated p53 protein determines the 
type of cellular response which range from activation of repair mechanisms, stopping cell cycle or 
indecent apoptosis and autophagy. When these normal biological responses have completed their 
protective role, the activation of p53 is reverted; otherwise it will be deleterious for the cell. The 
reversion is necessary because the persistent accumulation of p53 is deleterious to the cell by 
permanently blocking cell cycle or by induction of apoptosis, which are not compatible with life. But 
if cellular protection against stress is successful, the reversion of the effects induced by p53 allows 
cell cycle progression and cell survival. This reversion is achieved by p53 that, as part of its 
transcriptional response, induces HDM2 gene expression, which is its negative regulator. The hdm2 
protein is an E3 ubiquitin-ligase that ubiquitylates p53 in its C-terminal oligomerization domain and 
marks it for degradation in the proteasome [22-25] forming an autoregulatory loop [26]. In that way, 
the p53 response is turned off and the biological consequences of a persistent accumulation of p53 
prevented (Figure 1). The core of this autoregulatory mechanism is the formation of a complex 
between the p53 and hdm2 proteins. Hdm2 has a hydrophobic pocket in its N-terminal region, 
residues 26-108, that interacts with the hydrophobic side of an alpha helix in dephosphorylated p53 
[27]. The p53 interaction with hdm2 is blocked by phosphorylation of p53 in Ser15, Thr18 or Ser20, 
which alters the alpha helix [27], and thus prevents degradation of p53 in the proteasome [19]. Thus a 
functional interaction between p53 and mdm2 requires dephosphorylation of p53, a process that has 
received relatively little attention, but that is required for downregulation the deleterious 
consequences of a persistent accumulation of p53. 
 However, phosphorylation of p53 in response to viral infection has not been studied in 
general, although it is very likely to play an important role in viral infections and it might also be 
mediated by viral kinases in addition to cellular kinases. Thus no specific p53 phosphorylation 
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patterns are known in the context of most viral infections, with some exceptions such as EBV or HSV. 
All viral effects on the p53 pathway are very likely to be transient, since they will be important, and 
probably different, at different times within the viral life cycle in acute infections. Also it is not 
known how p53 responses are blocked in latent or chronic infections. 
 Alternatively, the p53-hdm2 interaction can also be altered by kinases targeting hdm2. Hdm2 
is phosphorylated by several cellular kinases, but the effect varies depending on the residue 
phosphorylated [28]. Some hdm2 phosphorylations facilitate degradation of p53. Thus, PI3-K/Akt, 
associated with survival signaling, phosphorylates hdm2 in residues Ser166 and Ser186 in close 
proximity to its nuclear localization and nuclear export signals [28], and these phosphorylations 
promote its nuclear accumulation and facilitate p53 degradation [29]. No viral kinase directly 
phosphorylating hdm2 has yet been identified, but alternatively it is possible that viruses might 
activate the cellular PI3-K/Akt pathway to reach a similar effect. Another kinases phosphorylate 
hdm2 in other residues leading to its degradation [28, 30], so that p53 is not ubiquitylated and cannot 
be degraded, thus p53 accumulates in cells because can induce cell death. ATM phosphorylates hdm2 
in Ser395 and induces mdm2 degradation, indirectly permitting p53 stabilization and accumulation 
because it cannot be degraded [31]. Also c-Abl phosphorylates hdm2 in multiple sites, but the most 
important is Tyr394, preventing downregulation of p53, which is accumulated inducing apoptosis 
[32]. Thus a virus by activation of this second type of hdm2 phosphorylation pathway can manipulate 
it for viral release. 
 Viral infections constitute a major type of cellular stress, but the role of p53 in this context 
has not been extensively characterized, and most of the information is derived from few viruses, 
although circumstantial evidence for its implication is available for many of them. The roles of the 
p53 protein can have a dual effect in viral infections, as an antiviral defense in the context of cellular 
stress response; or alternatively, because of its role in regulating cell cycle and cell death, might be 
targeted and adjusted by viral proteins to facilitate their own viral life cycle. In this overview we look 
at the role that manipulation of p53 might play in the pathogenesis of viral infections. Most viruses 
have acquired, through evolution and adaptation to host cells, strategies to interfere with p53 
functions. Thus, many viruses have at least one viral protein that directly interacts with p53. Although 
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the functional consequences of this interaction may vary, its consequences in the cell have received a 
relatively limited attention compared to other aspects of viral biology. Studies on temporal changes of 
p53, during short viral life cycles, have not in general being performed, particularly since p53 might 
even have different roles depending on the requirements and stage of the infection, such as viral 
replication, viral assembly or viral release, as well as of the phase of the cell cycle. Therefore, p53 
responses can be subverted by viruses in different ways for their adaptation to sequential stages in 
viral life cycles. Control of cell cycle progression can be manipulated to permit viral replication, and 
cell death can be a determinant factor for lytic phases, elimination of infected cells, or alternatively 
permit viral release, and thus is a prime target for biological selection in viral evolution and adaptation 
to host cells.  
 
Viral mechanisms for manipulation of p53-mediated responses 
Viruses can functionally interfere with p53 mediated cellular responses by several 
mechanisms in which different components of the p53-hdm2 autoregulatory loop are targeted by viral 
proteins. Among them are direct viral protein interactions with p53, phosphorylation of p53 by viral 
kinases, ubiquitylation of p53 by viral proteins, activation of hdm2 by viral proteins and other indirect 
mechanisms. These are outlined in Fig. 1, and summarized in Table 2. 
 
Interaction of viral proteins with p53 
The simplest mechanisms by which viruses can interfere with p53 are mediated by a direct interaction 
between viral proteins and p53, and thus alter p53 dependent functions like cell cycle or apoptosis. 
 
Papovaviruses. Papovaviruses are a group of small DNA viruses (SV40, JCV and BHK) whose role 
in human pathology is not clear. The large T-antigen of SV40 directly interacts with the p53 DNA 
binding domain and can inhibit p53 mediated responses [33, 34]. The crystal structure of this p53 
complex is known [35] and can be used for drug design.  Human JCV large-T protein inhibits viral 
DNA replication by interacting with the DNA binding-region of p53, which is where most p53 
mutations detected in cancer are located. Some p53 mutations result in loss of p53 large-T interaction, 
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as is the case with the frequent mutation at position R273 relieving the inhibition on viral replication, 
but not in the case of mutations in position R175 [36]. The oncogenic role of JCV is still controversial 
[37]. Interestingly in Merkel carcinoma cells, a malignancy with dermoneurendocrine origin and 
associated to MCPyV (Merkel cell polyomavirus), with a higher viral load there is a lower level of 
p53 protein [38], which can contribute to tumor cell survival, but how it contributes to viral life cycle 
is not known.  
  
Adenovirus: Adenoviruses mainly cause upper tract respiratory infections. In infected cells, the E1B  
protein of Mr 55,000 [29] binds to p53 in cooperation with E4-ORF6 protein, targets p53 for active 
degradation [39, 40] and thus inhibits p53 acetylation by pCAF [41], reducing gene expression of pro-
apoptotic Bax [42] and preventing apoptosis [43].  Another adenoviral protein, E4-ORF3 also 
inactivates p53 by forming a nuclear structure that induces de novo histone-3 methylation (H3K9m3) 
in heterochromatin located at promoters targeted by p53, in this way p53-dependent activation of 
transcription is blocked [44]. However, at a different time in infection a p53 dependent apoptosis is 
necessary for a productive adenoviral infection, in which p53 is important for the cytopathic effect, 
but the underlying mechanism is not known [45]. 
 
Epstein-Barr Virus: EBV is associated with endemic Burkitts lymphomas and nasopharyngeal 
carcinomas. EBV represents a very interesting case, since two viral proteins can interact with p53, one 
during latency and the other in the lytic phase. During latency, the EBNA3C protein directly interacts 
with the C-terminal region of p53, prevents binding to DNA and inhibits activation of transcription, 
by this mechanism it also rescues cells from the apoptosis induced by p53 [46, 47]. In the EBV switch 
from latent to lytic infection, the intermediate-early BZLF1 lytic viral transcription factor directly 
interacts with the C- terminal region of p53 [48, 49], and interferes with the transactivation of genes 
induced by p53 in lymphoid cells [48], which can be overcome by overexpression of p53 that inhibits 
the role of BZLF1 in the disruption of viral latency [48].  
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Human herpes virus 6B. Herpes viruses cause vesicular epithelial lesions. In HHV-6-infected cells, 
early in infection, the U14 protein coimmunoprecipitates and colocalizes with p53 in dot like 
particles. Both proteins, U14 and p53, are incorporated into virions suggesting that p53 is likely to 
play an important role in viral infection, which has not yet been characterized [50]. There is a second 
viral protein, ORF-1 (DR-7), which also binds to p53 and inhibits transcription in cells from 
Hodgkin’s lymphomas [51]. The loss of p53 in infected cells favors the induction of cytopathic 
effects. Also in cells infected with HHV6B there is phosphorylation of p53 in Ser20 induced by CK1 
(casein kinase 1) [52], this specific phosphorylation leads to stabilization and accumulation of p53 
[18]. All the data indicate that in epithelial cells, some of the functions of p53 leading to cell-cycle 
arrest and apoptosis is restrained in HHV6B infections [53]. 
 
HHV8 (Kaposi’s sarcoma herpesivirus): KSHV infection can cause three different types of tumors: 
Kaposi's sarcoma, a plasmablastic variant of multicentric Castelman's disease and an AIDS-related 
form of B cell lymphoproliferative disorder called primary effusion lymphoma (PEL), which is a very 
aggressive disease. KSHV has a protein named viral interferon regulatory factor 1 (vIRF1), or 
latency-associated nuclear antigen (LANA) [54, 55]; and another K-bZIP (open reading frame K8) 
protein that has a basic region-leucine zipper (bZIP) [56]. These proteins can interact with the DNA 
binding region of p53 and inhibit p53-dependent transcription [56].  LANA also facilitates p53 
ubiquitination leading to it removal by degradation in the proteasome and in that way contributes to 
viral persistence [57]. Furthermore, LANA/ vIRF1 can also interact with ATM, a DNA-damage 
response kinase, inhibiting its activity and resulting in a decrease in the p53 specific phosphorylation 
in S15 within its transactivation domain [58]. The functional result of the lack of p53 activation is a 
compromised cellular response to DNA damage mediated by p53, which may allow for progression of 
the viral infection when cellular stress responses are defective.  
 
Hepatitis B virus: HBV is the cause of most cases of hepatitis and hepatocarcinomas. In HBV 
infections p53 function is affected by a unique viral protein by two mechanisms. The HBV protein X 
(HBV X) represses TP53 gene expression [59], and also retains p53 in the cytoplasm causing a block 
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of p53 nuclear functions [60].  This process abrogates the infected cell response to genotoxic 
damage, and thus might contribute to oncogenesis by HBV [61]. But also in cells expressing HBV 
X, the phosphorylation of p53 in six residues within its N-terminal domain is not affected, 
particularly in Ser15 [62], which suggest a good stress response. These contradictory data reflects 
the existence of differential infection requirements that need to be clarified. Recently, a double 
mutation in HBV X (K130M and V130I) protein, which also interacts with p53, has been shown to 
inhibit p53-dependent transcription and colony formation [63]. 
 
HCV: Human hepatitis C virus is also implicated in liver cancer and liver failure. This virus expresses 
the NS5A protein that interacts with p53 blocking p53-dependent transcription and prevents apoptosis 
[64, 65], and in that way can contribute to tumour development.  
 
HIV-1: This virus causing AIDS expresses a protein vpr, which by its C-terminal region indirectly 
inhibits p53 activation of transcription, although this action does not require a direct interaction 
between these two proteins [66]. This inhibition of p53 derepresses the activation of HIV-1 mediated 
by the Sp1transcription factor [67, 68].  
 
Influenza: In cells infected with influenza virus, the non-structural NS1 protein of influenza A 
interacts directly with p53, inhibits activation of p53-dependent transcription and prevents induction 
of apoptosis [69], but some NS1 variants maintain the inhibition of transcription, but have no effect 
on apoptosis [70]. These data suggest a dual role for the NS1 protein that needs to be further 
characterized [71]. 
 
Phosphorylation of p53 by viral protein kinases  
Phosphorylation of p53 is a major mechanism regulating p53 functions [18]. But only one 
viral kinase has been identified so far; Vaccinia virus B1(B1R) kinase is able to extensively 
phosphorylate p53 [72]. This situation requires additional research because kinases might have 
potential uses as therapeutic targets for existing or novel kinase inhibitors [73]. Alternatively viral 
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proteins can affect cellular kinases and indirectly regulate p53, a topic particularly well known in 
some herpes viruses. Indirect phosphorylation by stabilization of p53 and disruption of the interaction 
with hdm2 will facilitate p53-induced effects. The phosphorylation of p53 in infected cells has been 
mainly studied in herpes viruses such as HSV [74], EBV [49], HCMV  [75]. 
 
Vaccinia virus: Poxviruses, of which vaccinia is the most characterized member, have an early protein 
B1R that is a ser-thr kinase [76]. B1R is necessary for viral DNA synthesis and replication of a large 
viral genome [77]. In addition to its roles regulating viral proteins, B1R also affects cellular proteins 
so contributing to its life cycle. It has been observed that infected cells have a delay in cell cycle 
progression [78]. B1R is able to phosphorylate the c-jun protein and modulate the cellular stress 
response to the viral infection [79]. Also B1R phosphorylates p53 in multiple sites causing a transient 
and short accumulation followed by its degradation [72]. This transient accumulation of p53 may be 
enough to delay cell cycle progression in order to permit viral DNA replication, after which the cycle 
can progress. The B1R gene was probably acquired by vaccinia during viral evolution and in this 
process some of the characteristics of the original cellular protein, VRK1, were lost to adjust its role 
to viral needs. This is exemplified by a relaxation of its kinase specificity, while the human VRK1 is 
very specific in the phosphorylation of cellular proteins as p53 in Thr18 [80-82] or c-Jun [83], B1R 
hyperphosphorylates in multiple residues both p53 [72] and c-Jun [79], another transcription factor 
implicated in stress responses [84]. This differential specificity may be in part due to the fact that 
vaccinia virus has only one kinase, B1R, and it has to play multiple roles in viral life cycle and 
pathogenesis. 
 
EBV. The BZLF1 protein promotes phosphorylation of p53 that prevents its interaction with hdm2 
and facilitates p53-dependent transcription at early stages of EBV infection [85].  But phosphorylation 
of p53 in its C-terminal region facilitates its degradation by interaction with non-mdm2 ubiquitin 
ligase [86, 87]. Thus at different phases of viral life cycle p53 has different and even opposite roles. 
Also in latent EBV infected cells the viral LMP1 protein indirectly induces multiple phosphorylation 
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of p53 within its transactivation domain and results in transcriptional activation that may contribute to 
viral latency and to eventual development of nasopharyngeal carcinomas [88]. 
 
HHV6B. In some HHVB6 infected cells there is an indirect phosphorylation of p53 in Ser392, within 
its oligomerization domain, which is probably mediated by an unknown kinase and independent of 
CK2 or p38 kinases [89]. More recently it has been shown that in these infected cells p53 is also 
phosphorylated in Ser20 by CK1 [52], which reflect the activation of a virally induced stress response 
that will facilitate binding to its transcriptional coactivator p300 and thus initiate host cell defensive 
actions.  
 
P53 acetylation interference  
Hepatitis C virus: HCV induces the expression of 3-beta-hydroxysterol Delta24-reductase (DHCR24), 
which prevents p53 acetylation in lysines 373 and 382, and non-acetylated p53 is not functional 
because it cannot induce gene expression [90]. Thus, the lack of a p53 response in HCV infected cells 
might contribute to viral persistence. 
 
Papillomaviruses: p53 acetylation interference paragraph. Recent data indicates that E6 of CRPV and 
HPV38 are able to prevent p300-mediated acetylation of p53 at lysine-382, probably through- a direct 
interaction with p300 [91]. This data is important because it is the first report demonstrating that the 
E6 protein of the skin cancer-associated papillomaviruses targets predominantly p53 acetylation via 
binding to p300, a transcriptional coactivator of p53, and does not induce degradation of p53 to 
immortalize primary keratinocytes and to induce tumors in an in vivo situation. 
 
HCMV: The HCMV IE2 protein also contributes to the functional inactivation of p53 by interacting 
with the histone acetyl-transferase activity of the p300 and CBP coactivators. This interaction reduces 
acetylation of p53 and histone H3 [92]. The non acetylated p53 is still transcriptionally active, but its 
antiapoptotic activity is inhibited, probably by a change in the selection of promoters targeted by p53, 
and thus the activity of IE2 can be considered as oncogenic [92]. 
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Adenovirus: This virus has the E1B protein that directly interacts with the acetyl transferase pCAF 
and also to a region near the p53 C-terminus in the region surrounding Lys320. The acetylation of p53 
in is blocked, but the acetylation of histones by PCAF is not affected, suggesting that E1B functions 
by preventing a correct interaction between p53 and PCAF[41]. 
 
Ubiquitylation of p53 by viral or cellular proteins 
Human Papillomavirus: HPV is associated with human cervical carcinoma, particularly types HPV16 
and HPV18. The HPV life cycle is associated with the maturation of the epithelium. Thus viral 
replication takes place in the basal layer and the transit amplifying compartment, while the formation 
of viral infective particles and expression of late genes occurs in the maturing layers of the epithelium, 
where keratinization takes place and there is no cell division.  HPV16 and HPV18 have an early gene, 
the E6 protein that is able to interact directly with the transactivation domain of p53 [93]. E6 is an E3 
ubiquitin ligase that promotes ubiquitylation and subsequent degradation of p53 by the proteasome in 
cells that are actively replicating HPV [94]. The loss of p53, and the subsequent loss of its repressive 
effect on cell cycle progression [95], maintain the epithelial cells in a proliferative state and thus 
allows viral replication. The loss of p53 facilitated the replication of HPV16 mediated by the viral E2 
protein [96, 97]. In addition the lack of p53 reduces the induction of apoptosis in infected cells 
preventing cell death and permits cell maturation to form infective viral particles. In HPV infected 
cells the effect of E6 on p53 is also accompanied by the interaction of E7 with retinoblastoma [98] 
resulting in a deregulation of the cell cycle independent of p53 [99]. The combined actions of both E6 
and E7 contribute to genomic instability by abrogating cell cycle checkpoints [100], a process that can 
generate additional mutations in the pathway towards cancer.  Recently it has been shown that an 
antagonist peptide against HPV16 E7 protein resulted in accumulation of p53 and induction of 
apoptosis by restoration of p53 activity, which in tumor xenographs showed therapeutic efficacy 
[101].  
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Hepes Simplex Virus: The ICP0 protein of HSV-1 is able to induce proteasome–dependent 
degradation of proteins and functions as an E3-ubiquitin ligase. ICP0 directly interacts with p53 
independent of its binding to USP7, an ubiquitin specific protease that also interacts with ICP10 
[102]. The loss of p53 induced by ICP0 thus interferes with the cellular ability to enter p53-mediated 
apoptosis, permitting the progression of the viral life cycle. But adenovirus ICP10 by sequestering 
USP7 can also induce a stabilization of p53, suggesting that the effects are different depending on the 
timing after infection [74]. 
 
EBV: During induction of EBV lytic cycle, there is a viral protein that facilitates p53 degradation by 
hdm2-independent ubiquitylation. The viral BZLF1 protein can function as a scaffold or adaptor of 
the ECS complex (Elongin B/C-cul2/5.SOCS-box protein), which is an ubiquitin ligase complex. This 
complex facilitates p53 degradation that has previously been phosphorylated in its C-terminal region 
and in that way downregulates the signal mediated by activated p53 [86, 87]. This complex regulation 
of p53 permits the execution of the different phases in the viral life cycle. 
 
KSHV: In cells infected by KSVH LANA can also serve as an adaptor molecule for an E3 ubiquitin 
complex via a specific protein motif. This stimulates ubiquitylation and degradation of p53 [103]. 
Moreover, another KSHV viral protein, KbZIP that interacts with p53, possesses SUMO activity and 
inhibits p53-dependent transcription in KSHV-infected cells [56]. As an alternative virus-mediated 
mechanism for p53 degradation there are viral proteins that themselves lack E3 ligase activity, such as 
the immunomodulatory KSHV lytic protein vIRF4, that are capable of forming multi-protein 
complexes with ubiquitin ligase activity components. As an example, vIRF4 has recently been shown 
to interact with MDM2 and to facilitate the proteasome-mediated degradation of p53 [104].  
 
Interaction of viral proteins with Hdm2  
Cytomegalovirus: Human cytomegalovirus (HCMV) expresses the IE2-86 protein that interacts with 
hdm2 [105] leading to its degradation and thus prevents p53 ubiquitylation [105], which accumulates 
in nuclei twelve hours after HCMV infection [106].  Although still permissive for viral infection, cells 
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lacking p53 show a decreased in accumulation of viral particles and a delay in viral DNA 
accumulation; these alterations can be recovered by normal p53, but not by p53 mutants. The 
expression of several viral proteins is altered in the absence of p53, such as the early replication 
protein UL44 and some of the late structural proteins, pp28 (UL99) and MCP (UL86). Localization of 
the major tegument protein pp65 (UL83) is also altered in p53(-/-) cells. Thus p53 appears to enhance 
HCMV replication and production of infectious virions [107].  
 Endothelial cells infected with HCMV are resistant to apoptosis [108, 109]. In infected 
endothelial cells there is an accumulation of p53, which is partly located in the cytosol as a result of 
blocking its nuclear localization signal and preventing its nuclear import, particularly in late stages of 
the infection [108, 109].  This is accompanied by a slowdown of the ubiquitylation [109], consistent 
with viral effect on hdm2. 
 HCMV infected fibroblasts [110, 111] present a senescence phenotype, accumulate p53 and 
have a hyperphosphorylated Rb, as well as an accumulation of the p16(INK4a) and reduction of 
p21[110]. This replicative senescence at early stages of infection increases the efficiency of infection 
and allows viral replication, effects that seem to be a consequence of the viral IE2-86 protein [110]. 
The IE2-86 protein induces Go/G1 and G1/S progression of the cell cycle, but then they slow down, 
probably as a consequence of its effect on p53, which is phosphorylated on Ser15 and acetylation 
resulting in its transcriptional activation and the increase in p16(Ink4a) and lack of p21 induction so 
that infected cells accumulate in the G2/M phase. Thus the dual effect of IE2 by inhibition of 
apoptosis and delay in cell cycle can permit completion of viral life cycle [111]. 
 
Hdm2 phosphorylation by Akt induced by viruses 
Influenza  ortho and paramixoviruses: Paramyxovirus and orthomyxoviruses interfere with p53 
function in a complex way. Influenza infected cells have higher levels of p53 [112, 113], which are 
transcriptionally active, in part mediated by phosphorylation of p53[114] and might induce apoptosis 
[71]. Influenza virus also triggers an anti-apoptotic signal, indirectly mediated by PI3K-Akt, a 
survival pathway, early in infection in order to protect cells from an early death, but at later stages of 
the life cycle it induces expression of p21 and induces an apoptotic response [112, 113] that is both 
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p53 dependent and independent [114]. Furthermore, p53 was required for virus induced cell-death 
[113], but the mechanism may in part be indirect and there might be an additional contribution by the 
induction of the interferon system [82]. One important component in this response partly mediated by 
p53 is due to modulation of the response by the phosphorylation of hdm2 by Akt [114]. Cells infected 
with influenza virus show an increase in the phosphorylation level of p53, which is dependent on the 
occurrence of viral RNA synthesis, indicating a cellular response to stress.  
Thus, influenza infection activates sequentially two routes affecting p53. Initially in infected 
cells there is an activation of the PI3K-AKT that phosphorylates hdm2, leading to its proteolytic 
degradation [115], and thus increasing p53 levels [30]. This results in accumulation of p53 and 
activation of p53 inducible genes such as p21, a cell cycle inhibitor, and bax leading to induction of 
cell death by accumulation of p53 [114, 115]. Thus influenza has a complex mechanism for 
modulating p53 dependent functions. 
 Paramyxoviruses are non-segmented negative-stranded RNA viruses and include viruses such 
as parainfluenza of which parainfluenza virus 5 (PIV5) is a prototype. Paramyxoviruses encode a 
protein V that plays a major role in regulation of viral RNA synthesis. This V protein has a conserved 
cysteine-rich C terminus that interacts with AKT [83]. AKT also contributes to a significant 
phosphorylation of P proteins from paramyxoviruses, which are essential cofactors in the viral RNA 
polymerase complex [115]. Inhibition of AKT reduces the level of PIV5 suggesting it is necessary for 
viral replication [115]. The role of Akt-mdm2-p53 is a well known regulatory mechanism of their 
functions [29, 30, 116]. 
 
Respiratory Syncytial virus: RSV, a paramyxovirus, is the cause of major respiratory problems and 
even death in infancy. RSV infects airway epithelial cells causing bronchiolitis in infants, and life-
threatening pneumonia in immunosuppressed individuals. RSV activates hdm2 shortly after infection, 
followed by a reduction in p53 levels [86]. RSV activates AKT, which phosphorylates and stabilizes 
hdm2, thus activating p53 degradation and causing a delay of apoptosis in primary human airway 
epithelial cells. This p53 down-regulation correlates with increased airway epithelial cell longevity, 
and this effect of RSV infection can be antagonized by nutlin-3 [117]. 
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Induction of p53 by interferon 
Many viruses induce interferon production in infected cells [118]. Type I interferons (IFN-alpha/beta) 
induce the transcription of tumor suppressor p53 and sensitize primary mouse embryonic fibroblasts 
to p53-mediated apoptosis by oncolytic viruses, such as vesicular stomatitis virus (VSV) [119]. But 
interferon can also induce downregulation of p53 levels in infected cells by VSV, probably reflecting 
different temporal roles during the infection [120]. A similar downregulation of p53 has also been 
observed in cells infected with several non-oncogenic viruses, including encephalomyocarditis virus 
and human parainfluenza virus type 3 [120]. These apparently contradictory effects may reflect a 
differential role for p53 in the course of the infection. 
  
p53 targeted therapies for viral infection control:  Prospects for antiviral therapies or virus-
associated diseases 
Infected cells are located in areas accessible to viral particles, and thus highly likely to also be 
reached by drugs. Antiviral therapies should not only be directed to the virus, but also to manipulate 
the response of the infected cell with a therapeutic purpose,  allowing the possibility of cutting short 
the initial spread of a viral infection, and in that way reducing its severity. The p53 pathway is the key 
element in the host cell stress response, including infections, and therefore might be a suitable target 
for pharmacological development. Some experimental evidence for an antiviral role for p53 has been 
demonstrated in the super-p53 mice, a mouse that contains three copies of the p53 gene, and express 
slightly higher levels of this protein [121]. These mice were more resistant to infection by VSV and 
replication because there is an increase in apoptosis as a consequence of p53, thus inhibiting the 
dissemination of the virus [122]. This illustrates that increasing p53 levels in infected cells might 
control an infection. 
 The p53 pathway is altered by mutations in many cancers, and is the subject of intense 
therapeutic interest [123-125], which can provide a conceptual framework for its application to viral 
infections. For example rescue of p53 function in lung tumors selectively affects the proliferating 
tumor cells, resulting in their elimination [126, 127]. Therefore, it seems reasonable than a similar 
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concept could be applied to the control of infectious diseases, particularly viruses. If p53 mediated 
responses are eliminated or interfered with in a variety of viral infections, it might be possible that 
some strategies aiming to recover or maintain p53 function might be of use to abort viral infections, 
which in some cases might be critical, such as in the control of their bioterrorist use, or in cases of 
acute effects requiring urgent attention. Among the infections that might be of interest are those 
related to poxviruses. An alternative use of p53 rescue drugs would be for application to latent or 
chronic viral infections with the aim of eliminating infected cells.  
Rescue mutations in cancer, of which Y220C is the paradigm, provided a structural 
framework for development of new p53 therapies [128]. But in the case of infections, p53 is a normal 
protein that interacts with a viral protein. Knowledge of the structure between p53 and proteins from 
pathogenic human viruses is necessary to have a framework to start developing novel drugs aiming at 
p53, which can be based on large screening targeting this interaction, but, unfortunately the structure 
of p53-viral protein is only known in the case of SV40 large T antigen [35]. 
Partial rescue of normal p53 function have been shown to interfere with the success of viral 
infection.  The reactivation of p53 function by preventing its degradation by hdm2, as is the case of 
nutlins might contribute to control of virus-induced diseases, since p53 accumulation will stop cell 
cycle and induce apoptosis. Some of the drugs used in the context of cancer have already been applied 
to control of infected cells; particularly the use of nutlins that interferes with the p53-mdm2 
interaction, peptides might also interfere with p53-viral protein interactions. Nutlins are small 
molecules that directly interact with the hdm2/mdm2 surface area required for hdm2 binding to p53; 
thus the binding of nutlins to mdm2 preventing the interaction with p53 and functionally rescuing 
p53-dependent functions [129]. Nutlins in control of viral infection might be useful if they induce cell 
death and thus interfere with the complete viral life cycle. Nutlin-3a induces massive level of 
apoptosis in cells harboring KSHV. In PEL (primary effusion lymphoma) cells the use of Nutlin-3a 
reactivates p53 induces massive level of apoptosis, suggesting this pathway was inactivated in these 
infected cells [130, 131]. Furthermore, the chemical reactivation of p53 by the Hdm2 antagonist 
Nutlin-3 led to unimpaired induction of p53 target genes as well as growth inhibition and apoptosis 
[132]. These results provide support for the use of p53 functional rescue with a therapeutic purpose. It 
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is not known if a similar effect can be achieved in other pathology caused by KSHV. Also, the effect 
of RSV infection can be antagonized by nutlin-3. Nutlin increases the level of p53 in RSV infected 
cells causing an early cell death [86]. These results are important as proof of concept for targeting p53 
functions in virally infected cells. The use of nutlin-3 in Burkitt lymphoma cells disrupts the 
interaction of p53 with mdm2 and facilitates induction of apoptosis [133]. Also in lymphoblastoid 
cells infected with EBV the treatment with nutlin-3A and p53 restoration there is an induction of 
apoptosis and thus interference with viral infection pointing to its potential usefulness with a 
therapeutic purpose [134].  
Very recently a novel p53 functional recue has been reported. In this approach the suppression 
of p53 by HdmX, an hdm2 related protein, can be overcome by stapling the p53 helix that should 
interact with HdmX resulting in an activation of p53 function [135]. In this approach the HdmX 
protein is blocked by a peptide containing two substitutions and derived from the p53 alpha-helix. 
These peptides also block the effect of Hdm2 [135]. 
The recovery of p53 function in infected cells can have two major applications. In acute 
infections the stabilization of p53 can result in its death before completion of viral life cycle, thus 
limiting the magnitude of the infection. This will be very useful for infections like poxviruses, or in 
the case of viruses such as Ebola, Lassa or hemorrhagic fevers, that have no treatment.  In these 
situations even some drug toxicity might acceptable given the short duration of the treatment and the 
dramatic consequences of these infections. In all cases it is of great interest to study the role of p53 
rescue drugs in animal models to identify new ways for controlling viral infections. The initial 
evidence obtained with RSV and KSHV clearly indicate what might become a very promising 
therapeutic approach. 
Another area of great potential but that has not received any attention in the context of 
antiviral therapies refers to the potential use of kinase inhibitors to control viral infections., 
particularly at a time in which there is a boom in development of kinase inhibitors. These inhibitors 
can target either kinases in cellular pathways used by viruses, or alternatively viral kinases. Among 
the cellular kinases, the PI3K-Akt pathway is a prime candidate since it is affected by some viruses 
(Table 1), such as RSV [117], and there is a large number of inhibitors available or in development 
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[136]. Regarding viral kinases, up to now only one the B1R kinase form poxviruses virus has been 
identified as affecting the pre pathway [72], thus development of specific inhibitors for this kinase is a 
challenge, since its eventual utilization includes viruses such as smallpox, which is a potential 
bioterrorist threat.   
The development of specific drugs targeting the interaction of p53 with viral proteins might 
provide a conceptual framework to design specific strategies to interfere with the viral life cycle. 
These drugs should interfere with the interaction between the viral protein and p53, so that this latter 
molecule can initiate the appropriate stress response to eliminate the infected cell before viral 
replication takes place. In this context viral kinases should receive more attention as specific targets 
for inhibition of viral functions. Particularly now, that the inhibition of many members the human 
kinome is the target of intense pharmaceutical research. Existing inhibitors of human kinases may 
affect viral life cycles; and is possibility that should also be explored with a therapeutic aim. 
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Table 1 
Viral mechanism of 
interference with p53 
Virus Viral Protein Ref. 
Inhibition of TP53 gene expression HIV1 Tat [66] 
Interaction with p53 DNA binding domain SV40 
JCV 
HHV8 (KSHV) 
HHV6B 
Adenovirus 
Influenza 
HCV 
Large T antigen 
Large T antigen 
K-bZIP (K8) 
U14 
E1B/E4-ORF6 
NS1 
NS5A 
[33] 
[36] 
[56] 
[50] 
[39, 40] 
[69] 
[65] 
Interaction with p53 C-terminus EBV (latent) 
EBV (lytic) 
KSHV 
EBNA-3C 
BZLF1 
K-bZIP 
[46, 47] 
[48] 
[56] 
p53 phosphorylation Vaccinia 
EBV 
B1R 
LMP1 (indirectly) 
[72] 
[88] 
Interaction with regulatory proteins (ATM) 
of p53 
HHV8 (KSHV) vIRF1/LANA [58] 
Inhibition of p53 dependent transcription HIV-1 
Adenovirus 
HBV 
HCV 
HHV6B 
Vpr (indirect) 
E4-ORF3 
X 
NS5A 
ORF-1(DR7) 
[68] 
[44] 
[61] 
[65] 
[51] 
Prevention of p53 acetylation 
(modifies specificity of p53-dependent  
transcription)  
HCV 
HCMV 
Adenovirus 
Induction of cellular DHCR24 
IE2-86 
E1B/E4-ORF6 
[90] 
[92] 
[41] 
Ubiquitylation of p53 by viral E3-Ubiqitin 
ligases 
HPV 
HSV 
HHV8(KSHV) 
EBV 
E6 
ICP0 
LANA (indirectly) 
BZLF1 (indirectly) 
[93]  
[102] 
[103] 
[86, 87] 
Phosphorylation  of mdm2 by Akt  RSV 
Influenza 
PIV5 
? 
? 
V protein 
[117] 
[112] 
[115] 
Interaction with hdm2 HCMV 
HHV8(KSHV) 
IE2-86 
vIRF4 
[105] 
[104] 
Indirect p53 downregulation induced by 
interferons 
EMCV 
HPIV3 
VSV 
 
 
[120] 
[120] 
[119, 120] 
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FIGURE LEGENDS 
 
 
Figure 1. Interaction between p53 and hdm2 and their autoregulatory loop. Steps where viruses 
interfere with the p53-hdm2 stress response to permit a successful viral life cycle. In the cases in 
which viruses inhibit p53 dependent transcription, the action of the viral protein has been placed in the 
branch or gene with which it has been reported, but other p53 dependent genes might also be affected. 
Vacc: vaccinia virus. SV40: simian virus 40. JCV: JC virus. Adv: Adenovirus. HCMV: human 
cytomegalovirus. Inf.: Influenza virus. HPV: human papillomaviruses.  HHV: human herpes virus. 
KSHV: Kaposi sarcoma herpes virus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
